跳转至内容
Merck
CN
  • Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients.

Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients.

Drugs & aging (2008-10-25)
Emmanuel Andrès, Thomas Vogel, Laure Federici, Jacques Zimmer, Georges Kaltenbach
摘要

The objective of this review is to evaluate the usefulness of oral cobalamin (vitamin B12) treatment in elderly patients. PubMed was systematically searched for English and French articles published from January 1990 to January 2007. Prospective randomized studies (n=3), a systematic review by the Cochrane group (n=1) and prospective studies in a well defined population (n=5) provide evidence that oral cobalamin therapy may adequately treat cobalamin deficiency in elderly patients. However, the current literature does not suggest a strategy in terms of the form (hydroxy- or cyanocobalamin), frequency and duration of the treatment. This review confirms the previously reported efficacy of oral cobalamin treatment in elderly patients. Oral cobalamin treatment avoids the discomfort, inconvenience and cost of monthly injections.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
维生素 B 12, ≥98%
Supelco
维生素B12, pharmaceutical secondary standard, certified reference material
Sigma-Aldrich
维生素 B 12, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Supelco
腈钴胺(维生素 B12), analytical standard
Supelco
维生素B12标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
氰钴胺, meets USP testing specifications
氰钴胺, European Pharmacopoeia (EP) Reference Standard